Avicanna Inc., a leading biopharmaceutical company specializing in plant-derived cannabinoid-based products, has unveiled the agenda for its 6th annual clinical symposium on cannabinoid therapeutics. Titled "From Emerging Evidence to Clinical Practice," the event is scheduled for June 11-12, 2026, at the MaRS Discovery District in Toronto, Ontario. This year's symposium marks a significant expansion, transitioning to a two-day format that will be accessible both in-person and virtually, reflecting growing interest and participation in the field.
Expanded Focus on Evidence-Based Clinical Dialogue
The symposium serves as a premier forum for evidence-based clinical discussion, interdisciplinary dialogue, and patient-centered considerations. It will bring together researchers, industry professionals, and healthcare practitioners from across Canada and internationally. Over the years, this event has facilitated collaboration among physicians, researchers, pharmacists, and other healthcare experts from academic and clinical settings, fostering research exchange and enhancing patient care strategies.
Key Agenda Highlights and Speaker Lineup
The 2026 program features an enriched agenda that includes presentations on new research findings, case-based clinical discussions, and multidisciplinary panels. Topics will cover prescribing practices, treatment planning, and patient management, addressing the integration of cannabinoid-based therapies into clinical practice while acknowledging existing evidence gaps and variability in guidance.
Notable speakers and their topics include:
- Dr. James MacKillop from McMaster University on the state of evidence for medical cannabis in Canada.
- Dr. Daniel Bear from Humber Polytechnic discussing cannabinoid science and evidence limitations.
- Dr. Evan Lewis from the University of Toronto leading a clinical workshop on practical approaches to prescribing medical cannabis.
- Dr. Hance Clarke from Toronto General Hospital presenting evidence from real-world studies on pain-related prescriptions.
- Erin Mignault, a nurse practitioner, focusing on women's health, specifically menopause and cannabinoid therapies.
Emphasis on Underrepresented Areas and Educational Resources
Karolina Urban, Executive Vice President of Medical Affairs at Avicanna, emphasized the symposium's deliberate focus on underrepresented areas such as women's health, evidence-informed care for veterans, and translating research into clinical decision-making. "This event provides a crucial platform for clinicians and researchers to review emerging evidence, share real-world experiences, and explore the role of cannabinoid-based therapies in patient care," she stated.
In addition to live sessions, the symposium will be recorded and made available through the Avicanna Academy, a growing library of clinical resources, recorded lectures, and educational materials designed to support ongoing professional development. Healthcare professionals interested in attending or showcasing their research are invited to register online or submit posters for consideration by the organizing committee, further promoting knowledge dissemination and collaboration in this evolving field.
